
Claims

1. A solid dispersion comprising  (ARN-509) and a poly(meth)acrylate copolymer.

2. The solid dispersion according to claim 1 wherein the dispersion consists of ARN-509 and a poly(meth)acrylate copolymer.

3. The solid dispersion according to claim 1 or 2 wherein the weight-by-weight ratio of ARN-509 : poly(meth)acrylate copolymer in the solid dispersion is in the range from 1 : 1 to 1 : 5.

4. The solid dispersion according to claim 3 wherein the weight-by-weight ratio of ARN-509 : poly(meth)acrylate copolymer in the solid dispersion is 1:2.

5. The solid dispersion according to claim 3 wherein the weight-by-weight ratio of ARN-509 : poly(meth)acrylate copolymer in the solid dispersion is 1:1.

6. The solid dispersion according to any one of the preceding claims wherein ARN-509 is present in amorphous form.

7. The solid dispersion according to any one of the preceding claims wherein the dispersion is a solid solution.

8. The solid dispersion according to any one of the preceding claims wherein the poly(meth)acrylate copolymer is poly(methacrylic acid-co-ethyl acrylate) 1:1.

9. The solid dispersion according to any one of the preceding claims obtainable by spray drying.

10. The solid dispersion according to any one of claims 1 to 8 obtainable by hot melt extrusion.

11. A particle consisting of a solid dispersion as defined in any one of the preceding claims.

12. A particle comprising a solid dispersion as defined in any one of claims 1 to 10.

13. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a solid dispersion according to any one of claims 1 to 10.

14. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a particle according to claim 11 or 12.

15. The formulation according to claim 13 or 14 wherein the formulation comprises 60 mg of ARN-509.

16. The formulation according to claim 13 or 14 wherein the formulation comprises 120 mg of ARN-509.

17. The formulation according to claim 13 or 14 wherein the formulation comprises 240 mg of ARN-509.

18. The formulation according to any one of claims 13 to 17 wherein the weight of the solid dispersion ranges from 20 to 40 % of the total weight of the formulation.

19. The formulation according to any one of claims 13 to 18 wherein the formulation is a tablet.

20. The formulation according to claim 19 which is suitable for oral administration.

21. A process for preparing the solid dispersion according to claim 9 comprising the steps of mixing ARN-509 and a poly(meth)acrylate copolymer in a suitable solvent and spray drying said mixture.

22. The process according to claim 21 wherein the suitable solvent is a mixture of dichloromethane and methanol.

23. The process according to claim 22 wherein the weight:weight ratio of dichloromethane to methanol in the mixture is 5:5.

24. Use of the pharmaceutical formulation according to any one of claims 13 to 20 for the preparation of a medicament for the treatment of prostate cancer.

25. Use according to claim 24 wherein the medicament is for oral administration.

26. A combination of a pharmaceutical formulation according to any one of claims 13 to 20 and another anticancer agent.

27. The combination according to claim 26 wherein the other anticancer agent is an androgen biosynthesis inhibitor.

28. The combination according to claim 26 wherein the other anticancer agent is abiraterone acetate.

29. The combination according to any one of claims 26 to 28 further comprising prednisone.